In this short Medscape video, David Kerr, Professor of Cancer Medicine at the University of Oxford, United Kingdom, and past President of ESMO, discusses the updated results of the FIRE-3 study, which were presented recently by the German/Austrian group at the 2013 European Cancer Congress. This is a front-line, randomized study comparing FOLFIRI plus bevacizumab vs FOLFIRI plus cetuximab. View the video here.
First time users may be asked to sign in.
No comments:
Post a Comment